Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03348228 · ClinicalTrials.gov registry record · NA
Effect of Hydroxycitrate on Urine Chemistry
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT03348228 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 18 participants.
The verdict
NCT03348228, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
Hydroxycitrate (HCA) is a compound extracted from the fruit, Garcinia Cambogia. Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. There has been recent evidence that hydroxycitrate is a potent inhibitor of calcium oxalate crystal growth and can lead to the dissolution of the crystals. The purpose of this research study is to study the effect of Hydroxycitrate (HCA) supplements on HCA urinary excretion and on urine chemistries in kidney stone formers and normal subjects.
Interventions
- DIETARY_SUPPLEMENT Hydroxycitrate (HCA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-10-04 |
| Est. Completion | 2020-12-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03348228
The ClinicalTrials.gov registry entry for NCT03348228 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydroxycitrate (HCA) is the first listed.
NCT03348228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03348228 about?
NCT03348228 is a clinical study titled "Effect of Hydroxycitrate on Urine Chemistry". Hydroxycitrate (HCA) is a compound extracted from the fruit, Garcinia Cambogia. Hydroxycitrate supplements are available over the counter and are primarily promoted as a weight loss supplement. There has been recent evidence that hydroxycitrate is a potent inhibitor of calcium oxalate crystal growth...
What is the current status of trial NCT03348228?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2018-10-04. Estimated completion is 2020-12-15.
What interventions are being tested in trial NCT03348228?
The interventions under investigation include: Hydroxycitrate (HCA) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03348228?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.